Display options
Share it on

Asian-Australas J Anim Sci. 2016 Jan;29(1):134-41. doi: 10.5713/ajas.15.0534.

Effect of Polysaccharides from Acanthopanax senticosus on Intestinal Mucosal Barrier of Escherichia coli Lipopolysaccharide Challenged Mice.

Asian-Australasian journal of animal sciences

Jie Han, Yunhe Xu, Di Yang, Ning Yu, Zishan Bai, Lianquan Bian

Affiliations

  1. College of Animal Husbandry and Veterinary, Liaoning Medical University, Jinzhou 121-001, China .
  2. Institute of Biotechnology Research, Liaoning Academy of Agricultural Sciences, Shenyang 1108-66, China .

PMID: 26732337 PMCID: PMC4698680 DOI: 10.5713/ajas.15.0534

Abstract

To investigate the role of polysaccharide from Acanthopanax senticosus (ASPS) in preventing lipopolysaccharide (LPS)-induced intestinal injury, 18 mice (at 5 wk of age) were assigned to three groups with 6 replicates of one mouse each. Mice were administrated by oral gavage with or without ASPS (300 mg/kg body weight) for 14 days and were injected with saline or LPS at 15 days. Intestinal samples were collected at 4 h post-challenge. The results showed that ASPS ameliorated LPS-induced deterioration of digestive ability of LPS-challenged mice, indicated by an increase in intestinal lactase activity (45%, p<0.05), and the intestinal morphology, as proved by improved villus height (20.84%, p<0.05) and villus height:crypt depth ratio (42%, p<0.05), and lower crypt depth in jejunum (15.55%, p<0.05), as well as enhanced intestinal tight junction proteins expression involving occludin-1 (71.43%, p<0.05). ASPS also prevented intestinal inflammation response, supported by decrease in intestinal inflammatory mediators including tumor necrosis factor α (22.28%, p<0.05) and heat shock protein (HSP70) (77.42%, p<0.05). In addition, intestinal mucus layers were also improved by ASPS, as indicated by the increase in number of goblet cells (24.89%, p<0.05) and intestinal trefoil peptide (17.75%, p<0.05). Finally, ASPS facilitated mRNA expression of epidermal growth factor (100%, p<0.05) and its receptor (200%, p<0.05) gene. These results indicate that ASPS can prevent intestinal mucosal barrier injury under inflammatory conditions, which may be associated with up-regulating gene mRNA expression of epidermal growth factor and its receptor.

Keywords: Epidermal Growth Factor; Herbal Extract; Inflammation; Intestinal Barrier; Metabolism; Pro-inflammatory Cytokines

References

  1. Int Immunopharmacol. 2003 Sep;3(9):1301-12 - PubMed
  2. Exp Cell Res. 2005 Feb 15;303(2):252-62 - PubMed
  3. J Lipid Res. 2010 Jun;51(6):1407-15 - PubMed
  4. Amino Acids. 2010 Jul;39(2):555-64 - PubMed
  5. Acta Pharmacol Sin. 2001 Dec;22(12):1057-70 - PubMed
  6. Burns. 2002 Dec;28(8):731-7 - PubMed
  7. Methods. 2001 Dec;25(4):402-8 - PubMed
  8. Asian-Australas J Anim Sci. 2014 Jul;27(7):1035-43 - PubMed
  9. J Anim Sci. 1997 Jul;75(7):1773-83 - PubMed
  10. Gastroenterology. 1987 Jan;92(1):98-105 - PubMed
  11. J Nutr. 2012 Nov;142(11):2017-24 - PubMed
  12. Br J Nutr. 2008 Sep;100(3):552-60 - PubMed
  13. Cell Mol Life Sci. 2005 Dec;62(24):2932-8 - PubMed
  14. Vet Immunol Immunopathol. 2005 May 1;105(1-2):151-61 - PubMed
  15. Gastroenterology. 1995 Feb;108(2):564-80 - PubMed
  16. Cell Mol Life Sci. 2005 Jan;62(1):10-23 - PubMed
  17. Arzneimittelforschung. 2001 Jan;51(1):76-83 - PubMed
  18. Dig Dis Sci. 2001 Sep;46(9):1899-908 - PubMed
  19. Food Chem. 2011 Jul 15;127(2):434-40 - PubMed
  20. J Surg Res. 1996 Jun;63(1):185-92 - PubMed
  21. J Nutr. 2004 Mar;134(3):641-7 - PubMed
  22. J Cell Physiol. 2005 Jul;204(1):83-6 - PubMed
  23. J Clin Invest. 1994 Jul;94(1):376-83 - PubMed
  24. Gastroenterology. 2000 Dec;119(6):1740-4 - PubMed
  25. Inflammation. 2000 Feb;24(1):33-44 - PubMed

Publication Types